Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
International journal of molecular sciences · 2026
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 4 institutions in 2 countries.
Angela LeoDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Erica PranziniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.ORCID 0000-0002-1668-2777
Laura PietrovitoDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Elisa PardellaDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.ORCID 0000-0001-5655-6428
Matteo ParriDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Paolo CirriDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Gennaro BrunoDivision of Pediatric Oncology/Hematology, Meyer University Children's Hospital, 50139 Florence, Italy.ORCID 0000-0001-6252-3825
Maura CalvaniDivision of Pediatric Oncology/Hematology, Meyer University Children's Hospital, 50139 Florence, Italy.ORCID 0000-0003-0750-4706
Silvia PeppicelliDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.ORCID 0000-0001-6459-0458
Eugenio TorreDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Maiko SasakiDepartment of Dermatology, Emory School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA.
Lily YangDepartment of Dermatology, Emory School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA.
Lei ZhuDepartment of Dermatology, Emory School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA.ORCID 0000-0002-1820-4795
Paola ChiarugiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Giovanni RaugeiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy.ORCID 0000-0003-1294-786X
Jack L ArbiserDepartment of Dermatology, Emory School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA.ORCID 0000-0002-6798-6383
Maria Letizia TaddeiDepartment of Experimental and Clinical Medicine, University of Florence, Viale Morgagni 50, 50134 Florence, Italy.ORCID 0000-0002-6867-0620
University of Florence · ITEmory and Henry College · USMeyer Children's Hospital · ITUnited States Department of Veterans Affairs · US
Funding
Associazione Italiana Ricerca sul Cancro (AIRC) 19515University of Florence Fondi ex 60%
6 · The paper itself
Abstract
Metastatic melanoma is characterized by poor prognosis and a low free-survival rate. Thanks to their high plasticity, melanoma cells are able to migrate exploiting different cell motility strategies, such as the rounded/amoeboid-type motility and the elongated/mesenchymal-type motility. In particular, the amoeboid motility strongly contributes to the dissemination of highly invasive melanoma cells and no treatment targeting this process is currently available for clinical application. Here, we tested Claisened Hexafluoro as a novel inhibitor of the amoeboid motility. Reported data demonstrate that Claisened Hexafluoro specifically inhibits melanoma cells moving through amoeboid motility by deregulating mitochondrial activity and activating the AMPK signaling. Moreover, Claisened Hexafluoro is able to interfere with the adhesion abilities and the stemness features of melanoma cells, thus decreasing the in vivo metastatic process. This evidence may contribute to pave the way for future possible therapeutic applications of Claisened Hexafluoro to counteract metastatic melanoma dissemination.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Claisened Hexafluoro Inhibits Metastatic Spreading of Amoeboid Melanoma Cells. · full record | OpenQuestion